Collegium Pharmaceutical, Inc. provides its 2026 full-year financial guidance and business update.
Key highlights include expected product revenues in the range of $805 million to $825 million and Jornay PM net revenue in the range of $190 million to $200 million. Adjusted EBITDA is expected in the range of $455 million to $475 million.
The company experienced record growth in 2025 and aims for continued success in 2026, driven by the performance of Jornay PM and revenue growth across their pain portfolio.
Financial Guidance for 2026
Product revenues expected: $805M-$825M. Jornay PM net revenue: $190M-$200M. Adjusted EBITDA: $455M-$475M.
Recent Business Highlights
Increased 2025 financial guidance to $775M-$785M for net revenue and $460M-$470M for adjusted EBITDA. Successfully closed a $980M syndicated credit facility.
Supply Agreements with Hikma
Agreements with Hikma Pharmaceuticals USA Inc. for authorized generic versions of Nucynta and Nucynta ER, with expected launches in 2026.
- The 2026 financial guidance reflects Collegium Pharmaceutical's strong position for future growth, particularly driven by the performance of Jornay PM.
- The successful credit facility closure and supply agreements with Hikma indicate strategic moves to support expansion and portfolio diversification.
Collegium Pharmaceutical's optimistic outlook for 2026, driven by revenue growth projections and strategic partnerships, reinforces its commitment to delivering value to both patients and shareholders.